Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis
Closed for comments This consultation ended on at Request commenting lead permission
2 Information about fedratinib
Marketing authorisation indication
2.1 Fedratinib (Inrebic, Celgene) has a marketing authorisation for 'the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naive or have been treated with ruxolitinib'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics.
Price
2.3 The list price of fedratinib is £6,120 for a 120‑capsule pack of 100 mg capsules (excluding VAT, company submission). The company has a commercial arrangement, which would have applied if the technology had been recommended.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation